Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.

DISCUSSION: Bullous lichen planus has been reported only rarely in the context of nivolumab therapy. The timeline for development of cutaneous adverse reactions under anti-PD1 immunotherapy may last weeks or months and regular monitoring is required. Withdrawal of immunotherapy should only be considered where the outcome under systemic corticosteroids is unfavourable.
PMID: 31982173 [PubMed - as supplied by publisher]

Source: Annales de Dermatologie et de Cenereologie - January 21, 2020 Category: Dermatology Authors: de Lorenzi C, André R, Vuilleumier A, Kaya G, Abosaleh M Tags: Ann Dermatol Venereol Source Type: research